

Carlo Conti

Of Counsel

Carlo Conti is an of counsel in the practice group life sciences and health law. He advises institutions and organizations on questions of life sciences and health law and on matters of governmental and administrative law. He is a member of a number of boards of directors.

He has many years of professional experience and deep knowledge of all areas of life sciences and health law, as well as governmental and administrative law. He held executive positions in the pharmaceutical industry for more than 15 years. Carlo Conti then served as member of the State Council for Basel-Stadt Canton where he was head of the public health department. He was also president of the Swiss Conference of Public Health Ministers and chairman of the board of Swiss DRG AG and vice-chairman of the agency council of Swissmedic.

Practice Areas:

Life Sciences and Health Law
Constitutional and Administrative Law
Corporate and Commercial

Functions:

Numerous mandates as President
or Member of the Board of Directors of various companies
President or Board Member of various organisations

Career:

2023	Of counsel Wenger Plattner
2016	Partner Wenger Plattner
2014	Of counsel Wenger Plattner
2000	Member and Vice-President of the Cantonal Government Basel-Stadt, Head of the Department of Public Health
1985	F. Hoffmann-La Roche AG, in senior management position Legal Department and Public Relations
1985	University of Basel (Dr. iur.)
1982	Attorney at Law
1978	University of Basel (lic. iur.)

Selected publications:

- *Drug & Medical Device Litigation 2024 - Practical cross-border insights into drug and medical device litigation*
In: The International Comparative Legal Guides (ICLG), Fifth Edition, London 2024, p. 142-150
- *Digital Health Laws and Regulations Switzerland 2024*
In: The International Comparative Legal Guides (ICLG), Fifth Edition, London 2024, p. 205-213



Contact

Dr. Carlo Conti
Attorney at Law
Wenger Plattner
Attorneys at Law Tax Advisors Public
Notaries
Aeschenvorstadt 55
4010 Basel

T +41 61 279 70 00
F +41 61 279 70 01
carlo.conti@wenger-plattner.ch

Admission:

Bar admission (1982)

Languages:

German, English, Italian, French

- *Drug & Medical Device Litigation 2023 - Practical cross-border insights into drug and medical device litigation*
In: The International Comparative Legal Guides (ICLG), Fourth Edition, London 2023, p. 135-142
- *GLI - Pricing & Reimbursement 2022*
GLI - Pricing & Reimbursement 2022, Fifth Edition, p. 218 - 227
- *Kommentar zu Art. 16a - 16c HMG*
In: Eichenberger/Jaisli/Richli (Hrsg.), Basler Kommentar zum Heilmittelgesetz, 2. Aufl., Basel, 2022
- *GLI - Pricing & Reimbursement 2021*
GLI - Pricing & Reimbursement 2021, Fourth Edition, p. 195 - 204
- *GLI - Pricing & Reimbursement 2020*
Every resident in Switzerland is mandatorily obliged to be covered by basic healthcare insurance which provides for a wide range of services. Persons with lower incomes are, in principle, granted reductions on the premiums payable for such basic healthcare insurance. Thus, every resident in Switzerland is granted access to affordable healthcare. In general, therapeutic products are only reimbursed if they are listed on the so-called specialty list. In order to be listed thereon, a medicinal product must be admitted by the competent Swiss authority, and must satisfy the criteria of effectiveness, functionality and economic efficiency, based on which the maximum price for the therapeutic product in question is determined.
- *The Pharma Legal Handbook Switzerland*
Regulatory, Pricing and Reimbursement Overview · Preclinical and Clinical Trial Requirements · Marketing, Manufacturing, Packaging and Labeling Advertising · Traditional Medicines and OTC Products · Product Liability · Patents and Trademarks · Regulatory Reforms | Pharma Board Room, London 2020
- *GLI - Pricing & Reimbursement 2019*
Every resident in Switzerland is mandatorily obliged to be covered by basic healthcare insurance which provides for a wide range of services. Persons with lower incomes are, in principle, granted reductions on the premiums payable for such basic healthcare insurance. Thus, every resident in Switzerland is granted access to affordable healthcare. In general, therapeutic products are only reimbursed if they are listed on the so-called specialty list. In order to be listed thereon, a medicinal product must be admitted by the competent Swiss authority, and has to satisfy the criteria of effectiveness, functionality and economic efficiency, based on which the maximum price for the therapeutic product in question is determined.
- *GLI - Pricing & Reimbursement 2018*
Every resident in Switzerland is mandatorily obliged to be covered by basic healthcare insurance which provides for a wide range of services. Persons with lower incomes are in principle granted reductions on the premiums payable for such basic healthcare insurance. Thus, every resident in Switzerland is granted access to affordable healthcare.
- *Versorgungsmanagement im Spannungsfeld zwischen Daten-, Patientenschutz und sektoralen Versorgungsgrenzen (in German)*
In: Versorgungsmanagement in Gesundheitssystemen, Rebscher Herbert / Kaufmann Stefan (Hrsg.), Heidelberg 2013, S. 139 ff.